Literature DB >> 20218979

Rho kinase and protein kinase C involvement in vascular smooth muscle myofilament calcium sensitization in arteries from diabetic rats.

I V Kizub1, O O Pavlova, C D Johnson, A I Soloviev, A V Zholos.   

Abstract

BACKGROUND AND
PURPOSE: Diabetes mellitus (DM) causes multiple dysfunctions including circulatory disorders such as cardiomyopathy, angiopathy, atherosclerosis and arterial hypertension. Rho kinase (ROCK) and protein kinase C (PKC) regulate vascular smooth muscle (VSM) Ca(2+) sensitivity, thus enhancing VSM contraction, and up-regulation of both enzymes in DM is well known. We postulated that in DM, Ca(2+) sensitization occurs in diabetic arteries due to increased ROCK and/or PKC activity. EXPERIMENTAL APPROACH: Rats were rendered hyperglycaemic by i.p. injection of streptozotocin. Age-matched control tissues were used for comparison. Contractile responses to phenylephrine (Phe) and different Ca(2+) concentrations were recorded, respectively, from intact and chemically permeabilized vascular rings from aorta, tail and mesenteric arteries. KEY
RESULTS: Diabetic tail and mesenteric arteries demonstrated markedly enhanced sensitivity to Phe while these changes were not observed in aorta. The ROCK inhibitor HA1077, but not the PKC inhibitor chelerythrine, caused significant reduction in sensitivity to agonist in diabetic vessels. Similar changes were observed for myofilament Ca(2+) sensitivity, which was again enhanced in DM in tail and mesenteric arteries, but not in aorta, and could be reduced by both the ROCK and PKC blockers. CONCLUSIONS AND IMPLICATIONS: We conclude that in DM enhanced myofilament Ca(2+) sensitivity is mainly manifested in muscular-type blood vessels and thus likely to contribute to the development of hypertension. Both PKC and, in particular, ROCK are involved in this phenomenon. This highlights their potential usefulness as drug targets in the pharmacological management of DM-associated vascular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20218979      PMCID: PMC2925495          DOI: 10.1111/j.1476-5381.2010.00666.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  Phosphorylation of CPI-17, an inhibitory phosphoprotein of smooth muscle myosin phosphatase, by Rho-kinase.

Authors:  M Koyama; M Ito; J Feng; T Seko; K Shiraki; K Takase; D J Hartshorne; T Nakano
Journal:  FEBS Lett       Date:  2000-06-23       Impact factor: 4.124

2.  Excitation-contraction coupling in pulmonary vascular smooth muscle involves tyrosine kinase and Rho kinase.

Authors:  L J Janssen; H Lu-Chao; S Netherton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-04       Impact factor: 5.464

Review 3.  Regulation and functions of Rho-associated kinase.

Authors:  M Amano; Y Fukata; K Kaibuchi
Journal:  Exp Cell Res       Date:  2000-11-25       Impact factor: 3.905

Review 4.  Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes.

Authors:  I Idris; S Gray; R Donnelly
Journal:  Diabetologia       Date:  2001-06       Impact factor: 10.122

5.  Specificity and mechanism of action of some commonly used protein kinase inhibitors.

Authors:  S P Davies; H Reddy; M Caivano; P Cohen
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

Review 6.  Protein kinase C activation and its pharmacological inhibition in vascular disease.

Authors:  M Meier; G L King
Journal:  Vasc Med       Date:  2000       Impact factor: 3.239

7.  Effects of PKC isozyme inhibitors on constrictor responses in the feline pulmonary vascular bed.

Authors:  B J De Witt; A D Kaye; I N Ibrahim; T J Bivalacqua; F M D'Souza; R E Banister; A S Arif; B D Nossaman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-01       Impact factor: 5.464

8.  Noradrenaline-induced changes in intracellular Ca(2+) and tension in mesenteric arteries from diabetic rats.

Authors:  W L Chow; L Zhang; K M MacLeod
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

9.  Altered L-type Ca(2+) channel currents in vascular smooth muscle cells from experimental diabetic rats.

Authors:  R Wang; Y Wu; G Tang; L Wu; S T Hanna
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-03       Impact factor: 4.733

10.  Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase.

Authors:  J Feng; M Ito; K Ichikawa; N Isaka; M Nishikawa; D J Hartshorne; T Nakano
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

View more
  20 in total

1.  Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy, apoptosis and fibrosis in rats.

Authors:  Tsung-Jung Ho; Chi-Chang Huang; Chih-Yang Huang; Wan-Teng Lin
Journal:  Eur J Appl Physiol       Date:  2011-12-09       Impact factor: 3.078

2.  Elevated Glucose Levels Promote Contractile and Cytoskeletal Gene Expression in Vascular Smooth Muscle via Rho/Protein Kinase C and Actin Polymerization.

Authors:  Tran Thi Hien; Karolina M Turczyńska; Diana Dahan; Mari Ekman; Mario Grossi; Johan Sjögren; Johan Nilsson; Thomas Braun; Thomas Boettger; Eliana Garcia-Vaz; Karin Stenkula; Karl Swärd; Maria F Gomez; Sebastian Albinsson
Journal:  J Biol Chem       Date:  2015-12-18       Impact factor: 5.157

3.  Contribution of Rho-kinase to membrane excitability of murine colonic smooth muscle.

Authors:  O Bayguinov; L Dwyer; H Kim; A Marklew; K M Sanders; S D Koh
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

4.  The effect of sub-chronic systemic ethanol treatment on corpus cavernosal smooth muscle contraction: the contribution of RhoA/Rho-kinase.

Authors:  Eda Karabal Kumcu; Fatma Aydinoglu; Erhan Astarci; Nuran Ogulener
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-04       Impact factor: 3.000

5.  Fasudil ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats: a possible role of Rho kinase.

Authors:  Amal Hofni; Basim A Shehata Messiha; Safwat A Mangoura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-05-11       Impact factor: 3.000

6.  Fasudil improves short-term echocardiographic parameters of diastolic function in patients with type 2 diabetes with preserved left ventricular ejection fraction: a pilot study.

Authors:  Rong Guo; Yang Su; Jing Yan; Hui Sun; Jiakang Wu; Weijing Liu; Yawei Xu
Journal:  Heart Vessels       Date:  2014-01-05       Impact factor: 2.037

7.  Increased availability of angiotensin AT 1 receptors leads to sustained arterial constriction to angiotensin II in diabetes - role for Rho-kinase activation.

Authors:  Zsolt Bagi; Attila Feher; James Cassuto; Komala Akula; Nazar Labinskyy; Gabor Kaley; Akos Koller
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

8.  Ser1928 phosphorylation by PKA stimulates the L-type Ca2+ channel CaV1.2 and vasoconstriction during acute hyperglycemia and diabetes.

Authors:  Matthew A Nystoriak; Madeline Nieves-Cintrón; Tommaso Patriarchi; Olivia R Buonarati; Maria Paz Prada; Stefano Morotti; Eleonora Grandi; Julia Dos Santos Fernandes; Katherine Forbush; Franz Hofmann; Kent C Sasse; John D Scott; Sean M Ward; Johannes W Hell; Manuel F Navedo
Journal:  Sci Signal       Date:  2017-01-24       Impact factor: 8.192

9.  Dissociation of hyperglycemia from altered vascular contraction and relaxation mechanisms in caveolin-1 null mice.

Authors:  Luminita H Pojoga; Tham M Yao; Lauren A Opsasnick; Amanda E Garza; Ossama M Reslan; Gail K Adler; Gordon H Williams; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2013-11-26       Impact factor: 4.030

10.  NO-Releasing Nanoparticles Ameliorate Detrusor Overactivity in Transgenic Sickle Cell Mice via Restored NO/ROCK Signaling.

Authors:  Serkan Karakus; Biljana Musicki; Mahantesh S Navati; Joel M Friedman; Kelvin P Davies; Arthur L Burnett
Journal:  J Pharmacol Exp Ther       Date:  2020-03-06       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.